4CPS-092 Statistical relationship between biomarkers with prognostic value in anti-PDL1 treatments in cancer patients
Background and ImportanceThe prognostic value of biomarkers such as neutrophil/lymphocyte ratio (NLR), derived neutrophil/lymphocyte ratio (dNLR) and platelet/lymphocyte ratio (PLR) is increasingly studied, showing their usefulness in patients with different anti-PDL1 treatments in the context of on...
Gespeichert in:
| Veröffentlicht in: | European journal of hospital pharmacy. Science and practice 2023-03, Vol.30 (Suppl 1), p.A53-A53 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | A53 |
|---|---|
| container_issue | Suppl 1 |
| container_start_page | A53 |
| container_title | European journal of hospital pharmacy. Science and practice |
| container_volume | 30 |
| creator | Toledo Davia, MA Labrador Andujar, N Rubio Salvador, AR Blazquez Romero, C Torralba Fernandez, L Jimenez Mendez, C Prieto Galindo, R Dominguez Barahona, A Aguado Barroso, P Gomez Fernandez, E Moya Gomez, P |
| description | Background and ImportanceThe prognostic value of biomarkers such as neutrophil/lymphocyte ratio (NLR), derived neutrophil/lymphocyte ratio (dNLR) and platelet/lymphocyte ratio (PLR) is increasingly studied, showing their usefulness in patients with different anti-PDL1 treatments in the context of oncological pathologies.Aim and ObjectivesTo analyse whether there is a statistical relationship between these three parameters and to analyse the biomarkers and to analyse their effect on survival.Material and MethodsObservational and retrospective study in patients treated with pembrolizumab and diagnosed with non-small-cell lung cancer (NSCLC) in a tertiary level hospital. Demographic variables (sex and age) were collected, NLR as neutrophil/lymphocyte count, dNLR as neutrophil/leukocyte/neutrophil count and PLR as platelet/lymphocyte count were calculated. Progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method and log-rank test as a hypothesis test. The cut-off points were NLR=5, dNLR=3 and PLR=200. Spearman’s correlation test was used to check the correlation between the three biomarkers (previously the non-normality of the samples was checked by Kolmogorov-Smirnov test).ResultsA total of 74 patients treated with pembrolizumab were registered, 59 men (80,8%) and 14 women, with a median age of 65 [83-37] years. Median neutrophil count was 5.45 [6.1-1.5] x109neut/L, lymphocyte count was 1.45 [3.9-0.2] x109linf/L and platelet count was 174.7 [56.92-1345] x109 platelets/L. Table 1 shows the survival results obtained.Abstract 4CPS-092 Table 1Results of Kaplan-Meier survival method and log-rank test Progression-free survival Overwal survival Median IC95% (months) p LR-t Median IC95% (months) p LR-t NLR5 (n=29) 12,5 (5,1-19,9) 17,4 (9,1-25,6) dNLR3 (n=26) 11,5 (13,7-19,3) 17,09 (8,2-25) PLR200 (n=26) 9,97 (2,86-17,1) 11,31 (3,86-18,79) Spearman’s correlation test showed statistical significance in the relationship between the three biomarkers showing a strong association between them, Spearman’s coefficients obtained are shown: NLR-dNLR 0.934 (p=0), NLR-PLR 0.697 (p=0) dNLR-PLR 0.616 (p=0).Conclusion and RelevanceFor the three biomarkers there are significant differences in survival outcomes for the selected cut-off points, offering prognostic v |
| doi_str_mv | 10.1136/ejhpharm-2023-eahp.112 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_bmj_j</sourceid><recordid>TN_cdi_proquest_journals_2790228398</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2790228398</sourcerecordid><originalsourceid>FETCH-LOGICAL-b1192-3e8d48b9a8c32338b20b65eef128702060d47c693d3f323d0975d2bc4d7874a53</originalsourceid><addsrcrecordid>eNpFkMtOwzAQRS0EEhX0F5Al1gZ77CT2EpWnVIlKhXVkJy5xSZ3guHTLhh_lS3BUHquZubozc3UQOmP0gjGeX9p10zc6bAhQ4MTqpk86HKAJUFEQpXJx-Ndn-TGaDoMzNONcKsHVBO3EbLEkVMHXx-cy6uiG6Crd4mDbNHR-aFyPjY07az02rtvo8GrDgHcuNrgP3Yvvxg38rtutxc5j7aMji-s5wzFYHTfWx2HUK-0rG3Cfro7SKTpa6Xaw0596gp5vb55m92T-ePcwu5oTw5gCwq2shTRKy4pDCm2AmjyzdsVAFhRoTmtRVLniNV8lQ01VkdVgKlEXshA64yfofH83ZX3b2iGW624bfHpZQqEogORKJhfsXWaz_jcwWo6My1_G5ci4HBknHfg3QxV0UQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2790228398</pqid></control><display><type>article</type><title>4CPS-092 Statistical relationship between biomarkers with prognostic value in anti-PDL1 treatments in cancer patients</title><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Toledo Davia, MA ; Labrador Andujar, N ; Rubio Salvador, AR ; Blazquez Romero, C ; Torralba Fernandez, L ; Jimenez Mendez, C ; Prieto Galindo, R ; Dominguez Barahona, A ; Aguado Barroso, P ; Gomez Fernandez, E ; Moya Gomez, P</creator><creatorcontrib>Toledo Davia, MA ; Labrador Andujar, N ; Rubio Salvador, AR ; Blazquez Romero, C ; Torralba Fernandez, L ; Jimenez Mendez, C ; Prieto Galindo, R ; Dominguez Barahona, A ; Aguado Barroso, P ; Gomez Fernandez, E ; Moya Gomez, P</creatorcontrib><description>Background and ImportanceThe prognostic value of biomarkers such as neutrophil/lymphocyte ratio (NLR), derived neutrophil/lymphocyte ratio (dNLR) and platelet/lymphocyte ratio (PLR) is increasingly studied, showing their usefulness in patients with different anti-PDL1 treatments in the context of oncological pathologies.Aim and ObjectivesTo analyse whether there is a statistical relationship between these three parameters and to analyse the biomarkers and to analyse their effect on survival.Material and MethodsObservational and retrospective study in patients treated with pembrolizumab and diagnosed with non-small-cell lung cancer (NSCLC) in a tertiary level hospital. Demographic variables (sex and age) were collected, NLR as neutrophil/lymphocyte count, dNLR as neutrophil/leukocyte/neutrophil count and PLR as platelet/lymphocyte count were calculated. Progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method and log-rank test as a hypothesis test. The cut-off points were NLR=5, dNLR=3 and PLR=200. Spearman’s correlation test was used to check the correlation between the three biomarkers (previously the non-normality of the samples was checked by Kolmogorov-Smirnov test).ResultsA total of 74 patients treated with pembrolizumab were registered, 59 men (80,8%) and 14 women, with a median age of 65 [83-37] years. Median neutrophil count was 5.45 [6.1-1.5] x109neut/L, lymphocyte count was 1.45 [3.9-0.2] x109linf/L and platelet count was 174.7 [56.92-1345] x109 platelets/L. Table 1 shows the survival results obtained.Abstract 4CPS-092 Table 1Results of Kaplan-Meier survival method and log-rank test Progression-free survival Overwal survival Median IC95% (months) p LR-t Median IC95% (months) p LR-t NLR<5 (n=41) 16,1 (10,5-21,6) 0,05 24,9 (18,5-31,3) 0,01 NLR>5 (n=29) 12,5 (5,1-19,9) 17,4 (9,1-25,6) dNLR<3 (n=42) 14,65 (9-20) 0,09 23 (17,1-30,6) 0,04 dNRL>3 (n=26) 11,5 (13,7-19,3) 17,09 (8,2-25) PLR<200 (n=42) 15,6 (10,15-21,1) 0,04 26,25 (19,87-32,64) 0,001 PLR>200 (n=26) 9,97 (2,86-17,1) 11,31 (3,86-18,79) Spearman’s correlation test showed statistical significance in the relationship between the three biomarkers showing a strong association between them, Spearman’s coefficients obtained are shown: NLR-dNLR 0.934 (p=0), NLR-PLR 0.697 (p=0) dNLR-PLR 0.616 (p=0).Conclusion and RelevanceFor the three biomarkers there are significant differences in survival outcomes for the selected cut-off points, offering prognostic value for our patients. Spearman’s test indicates that there is a correlation between the biomarkers.References and/or AcknowledgementsConflict of InterestNo conflict of interest</description><identifier>ISSN: 2047-9956</identifier><identifier>EISSN: 2047-9964</identifier><identifier>DOI: 10.1136/ejhpharm-2023-eahp.112</identifier><language>eng</language><publisher>London: British Medical Journal Publishing Group</publisher><subject>Biomarkers ; Conflicts of interest ; Lymphocytes ; Neutrophils ; Section 4: Clinical pharmacy services</subject><ispartof>European journal of hospital pharmacy. Science and practice, 2023-03, Vol.30 (Suppl 1), p.A53-A53</ispartof><rights>European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ.</rights><rights>2023 European Association of Hospital Pharmacists 2023. No commercial re-use. See rights and permissions. Published by BMJ.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Toledo Davia, MA</creatorcontrib><creatorcontrib>Labrador Andujar, N</creatorcontrib><creatorcontrib>Rubio Salvador, AR</creatorcontrib><creatorcontrib>Blazquez Romero, C</creatorcontrib><creatorcontrib>Torralba Fernandez, L</creatorcontrib><creatorcontrib>Jimenez Mendez, C</creatorcontrib><creatorcontrib>Prieto Galindo, R</creatorcontrib><creatorcontrib>Dominguez Barahona, A</creatorcontrib><creatorcontrib>Aguado Barroso, P</creatorcontrib><creatorcontrib>Gomez Fernandez, E</creatorcontrib><creatorcontrib>Moya Gomez, P</creatorcontrib><title>4CPS-092 Statistical relationship between biomarkers with prognostic value in anti-PDL1 treatments in cancer patients</title><title>European journal of hospital pharmacy. Science and practice</title><addtitle>Eur J Hosp Pharm</addtitle><description>Background and ImportanceThe prognostic value of biomarkers such as neutrophil/lymphocyte ratio (NLR), derived neutrophil/lymphocyte ratio (dNLR) and platelet/lymphocyte ratio (PLR) is increasingly studied, showing their usefulness in patients with different anti-PDL1 treatments in the context of oncological pathologies.Aim and ObjectivesTo analyse whether there is a statistical relationship between these three parameters and to analyse the biomarkers and to analyse their effect on survival.Material and MethodsObservational and retrospective study in patients treated with pembrolizumab and diagnosed with non-small-cell lung cancer (NSCLC) in a tertiary level hospital. Demographic variables (sex and age) were collected, NLR as neutrophil/lymphocyte count, dNLR as neutrophil/leukocyte/neutrophil count and PLR as platelet/lymphocyte count were calculated. Progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method and log-rank test as a hypothesis test. The cut-off points were NLR=5, dNLR=3 and PLR=200. Spearman’s correlation test was used to check the correlation between the three biomarkers (previously the non-normality of the samples was checked by Kolmogorov-Smirnov test).ResultsA total of 74 patients treated with pembrolizumab were registered, 59 men (80,8%) and 14 women, with a median age of 65 [83-37] years. Median neutrophil count was 5.45 [6.1-1.5] x109neut/L, lymphocyte count was 1.45 [3.9-0.2] x109linf/L and platelet count was 174.7 [56.92-1345] x109 platelets/L. Table 1 shows the survival results obtained.Abstract 4CPS-092 Table 1Results of Kaplan-Meier survival method and log-rank test Progression-free survival Overwal survival Median IC95% (months) p LR-t Median IC95% (months) p LR-t NLR<5 (n=41) 16,1 (10,5-21,6) 0,05 24,9 (18,5-31,3) 0,01 NLR>5 (n=29) 12,5 (5,1-19,9) 17,4 (9,1-25,6) dNLR<3 (n=42) 14,65 (9-20) 0,09 23 (17,1-30,6) 0,04 dNRL>3 (n=26) 11,5 (13,7-19,3) 17,09 (8,2-25) PLR<200 (n=42) 15,6 (10,15-21,1) 0,04 26,25 (19,87-32,64) 0,001 PLR>200 (n=26) 9,97 (2,86-17,1) 11,31 (3,86-18,79) Spearman’s correlation test showed statistical significance in the relationship between the three biomarkers showing a strong association between them, Spearman’s coefficients obtained are shown: NLR-dNLR 0.934 (p=0), NLR-PLR 0.697 (p=0) dNLR-PLR 0.616 (p=0).Conclusion and RelevanceFor the three biomarkers there are significant differences in survival outcomes for the selected cut-off points, offering prognostic value for our patients. Spearman’s test indicates that there is a correlation between the biomarkers.References and/or AcknowledgementsConflict of InterestNo conflict of interest</description><subject>Biomarkers</subject><subject>Conflicts of interest</subject><subject>Lymphocytes</subject><subject>Neutrophils</subject><subject>Section 4: Clinical pharmacy services</subject><issn>2047-9956</issn><issn>2047-9964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNpFkMtOwzAQRS0EEhX0F5Al1gZ77CT2EpWnVIlKhXVkJy5xSZ3guHTLhh_lS3BUHquZubozc3UQOmP0gjGeX9p10zc6bAhQ4MTqpk86HKAJUFEQpXJx-Ndn-TGaDoMzNONcKsHVBO3EbLEkVMHXx-cy6uiG6Crd4mDbNHR-aFyPjY07az02rtvo8GrDgHcuNrgP3Yvvxg38rtutxc5j7aMji-s5wzFYHTfWx2HUK-0rG3Cfro7SKTpa6Xaw0596gp5vb55m92T-ePcwu5oTw5gCwq2shTRKy4pDCm2AmjyzdsVAFhRoTmtRVLniNV8lQ01VkdVgKlEXshA64yfofH83ZX3b2iGW624bfHpZQqEogORKJhfsXWaz_jcwWo6My1_G5ci4HBknHfg3QxV0UQ</recordid><startdate>20230323</startdate><enddate>20230323</enddate><creator>Toledo Davia, MA</creator><creator>Labrador Andujar, N</creator><creator>Rubio Salvador, AR</creator><creator>Blazquez Romero, C</creator><creator>Torralba Fernandez, L</creator><creator>Jimenez Mendez, C</creator><creator>Prieto Galindo, R</creator><creator>Dominguez Barahona, A</creator><creator>Aguado Barroso, P</creator><creator>Gomez Fernandez, E</creator><creator>Moya Gomez, P</creator><general>British Medical Journal Publishing Group</general><general>BMJ Publishing Group LTD</general><scope>K9.</scope></search><sort><creationdate>20230323</creationdate><title>4CPS-092 Statistical relationship between biomarkers with prognostic value in anti-PDL1 treatments in cancer patients</title><author>Toledo Davia, MA ; Labrador Andujar, N ; Rubio Salvador, AR ; Blazquez Romero, C ; Torralba Fernandez, L ; Jimenez Mendez, C ; Prieto Galindo, R ; Dominguez Barahona, A ; Aguado Barroso, P ; Gomez Fernandez, E ; Moya Gomez, P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b1192-3e8d48b9a8c32338b20b65eef128702060d47c693d3f323d0975d2bc4d7874a53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Biomarkers</topic><topic>Conflicts of interest</topic><topic>Lymphocytes</topic><topic>Neutrophils</topic><topic>Section 4: Clinical pharmacy services</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Toledo Davia, MA</creatorcontrib><creatorcontrib>Labrador Andujar, N</creatorcontrib><creatorcontrib>Rubio Salvador, AR</creatorcontrib><creatorcontrib>Blazquez Romero, C</creatorcontrib><creatorcontrib>Torralba Fernandez, L</creatorcontrib><creatorcontrib>Jimenez Mendez, C</creatorcontrib><creatorcontrib>Prieto Galindo, R</creatorcontrib><creatorcontrib>Dominguez Barahona, A</creatorcontrib><creatorcontrib>Aguado Barroso, P</creatorcontrib><creatorcontrib>Gomez Fernandez, E</creatorcontrib><creatorcontrib>Moya Gomez, P</creatorcontrib><collection>ProQuest Health & Medical Complete (Alumni)</collection><jtitle>European journal of hospital pharmacy. Science and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Toledo Davia, MA</au><au>Labrador Andujar, N</au><au>Rubio Salvador, AR</au><au>Blazquez Romero, C</au><au>Torralba Fernandez, L</au><au>Jimenez Mendez, C</au><au>Prieto Galindo, R</au><au>Dominguez Barahona, A</au><au>Aguado Barroso, P</au><au>Gomez Fernandez, E</au><au>Moya Gomez, P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>4CPS-092 Statistical relationship between biomarkers with prognostic value in anti-PDL1 treatments in cancer patients</atitle><jtitle>European journal of hospital pharmacy. Science and practice</jtitle><stitle>Eur J Hosp Pharm</stitle><date>2023-03-23</date><risdate>2023</risdate><volume>30</volume><issue>Suppl 1</issue><spage>A53</spage><epage>A53</epage><pages>A53-A53</pages><issn>2047-9956</issn><eissn>2047-9964</eissn><abstract>Background and ImportanceThe prognostic value of biomarkers such as neutrophil/lymphocyte ratio (NLR), derived neutrophil/lymphocyte ratio (dNLR) and platelet/lymphocyte ratio (PLR) is increasingly studied, showing their usefulness in patients with different anti-PDL1 treatments in the context of oncological pathologies.Aim and ObjectivesTo analyse whether there is a statistical relationship between these three parameters and to analyse the biomarkers and to analyse their effect on survival.Material and MethodsObservational and retrospective study in patients treated with pembrolizumab and diagnosed with non-small-cell lung cancer (NSCLC) in a tertiary level hospital. Demographic variables (sex and age) were collected, NLR as neutrophil/lymphocyte count, dNLR as neutrophil/leukocyte/neutrophil count and PLR as platelet/lymphocyte count were calculated. Progression-free survival (PFS) and overall survival (OS) were calculated using the Kaplan-Meier method and log-rank test as a hypothesis test. The cut-off points were NLR=5, dNLR=3 and PLR=200. Spearman’s correlation test was used to check the correlation between the three biomarkers (previously the non-normality of the samples was checked by Kolmogorov-Smirnov test).ResultsA total of 74 patients treated with pembrolizumab were registered, 59 men (80,8%) and 14 women, with a median age of 65 [83-37] years. Median neutrophil count was 5.45 [6.1-1.5] x109neut/L, lymphocyte count was 1.45 [3.9-0.2] x109linf/L and platelet count was 174.7 [56.92-1345] x109 platelets/L. Table 1 shows the survival results obtained.Abstract 4CPS-092 Table 1Results of Kaplan-Meier survival method and log-rank test Progression-free survival Overwal survival Median IC95% (months) p LR-t Median IC95% (months) p LR-t NLR<5 (n=41) 16,1 (10,5-21,6) 0,05 24,9 (18,5-31,3) 0,01 NLR>5 (n=29) 12,5 (5,1-19,9) 17,4 (9,1-25,6) dNLR<3 (n=42) 14,65 (9-20) 0,09 23 (17,1-30,6) 0,04 dNRL>3 (n=26) 11,5 (13,7-19,3) 17,09 (8,2-25) PLR<200 (n=42) 15,6 (10,15-21,1) 0,04 26,25 (19,87-32,64) 0,001 PLR>200 (n=26) 9,97 (2,86-17,1) 11,31 (3,86-18,79) Spearman’s correlation test showed statistical significance in the relationship between the three biomarkers showing a strong association between them, Spearman’s coefficients obtained are shown: NLR-dNLR 0.934 (p=0), NLR-PLR 0.697 (p=0) dNLR-PLR 0.616 (p=0).Conclusion and RelevanceFor the three biomarkers there are significant differences in survival outcomes for the selected cut-off points, offering prognostic value for our patients. Spearman’s test indicates that there is a correlation between the biomarkers.References and/or AcknowledgementsConflict of InterestNo conflict of interest</abstract><cop>London</cop><pub>British Medical Journal Publishing Group</pub><doi>10.1136/ejhpharm-2023-eahp.112</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2047-9956 |
| ispartof | European journal of hospital pharmacy. Science and practice, 2023-03, Vol.30 (Suppl 1), p.A53-A53 |
| issn | 2047-9956 2047-9964 |
| language | eng |
| recordid | cdi_proquest_journals_2790228398 |
| source | EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Biomarkers Conflicts of interest Lymphocytes Neutrophils Section 4: Clinical pharmacy services |
| title | 4CPS-092 Statistical relationship between biomarkers with prognostic value in anti-PDL1 treatments in cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T19%3A18%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_bmj_j&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=4CPS-092%E2%80%85Statistical%20relationship%20between%20biomarkers%20with%20prognostic%20value%20in%20anti-PDL1%20treatments%20in%20cancer%20patients&rft.jtitle=European%20journal%20of%20hospital%20pharmacy.%20Science%20and%20practice&rft.au=Toledo%20Davia,%20MA&rft.date=2023-03-23&rft.volume=30&rft.issue=Suppl%201&rft.spage=A53&rft.epage=A53&rft.pages=A53-A53&rft.issn=2047-9956&rft.eissn=2047-9964&rft_id=info:doi/10.1136/ejhpharm-2023-eahp.112&rft_dat=%3Cproquest_bmj_j%3E2790228398%3C/proquest_bmj_j%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2790228398&rft_id=info:pmid/&rfr_iscdi=true |